🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cologne
Clinical trial register · Germany

Clinical Trials in Cologne, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca48 Novartis Pharmaceuticals29 University of Cologne25 Janssen Research & Development, LLC21 Bristol-Myers Squibb21
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Cologne

612 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment
NCT06033274Tricuspid Regurgitation
Montefiore Medical Center
Observational
800
Munich, Frankfurt am Main, Essen, Lübeck, Bad Oeynhausen, Cologne, Hamburg
2023-10-05
Active, closed
German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa
NCT06095713Fabry Disease
DrugPegunigalsidase-alfa
Universität Münster
Observational
60
Berlin, Cologne, Hamburg, Hanover, Mainz, Müllheim, Münster, Würzburg
2023-10-01
Recruiting
Post-Market Clinical Follow Up Study With Navitor Valve
NCT06008080Aortic Stenosis
Abbott Medical Devices
Observational
1,000
Bad Bevensen, Berlin, Cologne, Dortmund, Erlangen, Frankfurt, Hamburg, Kiel
2023-09-29
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Berlin, Brandenburg an der Havel, Chemnitz, Cologne, Düsseldorf, Erlangen, Essen, Frankfurt
2023-09-18
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Freiburg I. Breisgau, Munich, Münnerstadt, Hamburg, Immenhausen, Marburg, Essen, Cologne
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Minden, Mainz, Cologne, Düsseldorf, Tübingen
2023-09-13
Active, closed
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
270
Würzburg, Cologne, Leipzig, Magdeburg, Berlin, Düsseldorf, Erlangen
2023-09-13
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Göttingen, Hamburg, Hanover
2023-09-11
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
DrugsCyclophosphamid·Rituximab
Alentis Therapeutics AG
Phase 2
80
Berlin, Cologne, Dresden, Essen, Hanover, Leipzig, Lübeck, München
2023-09-07
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
420
Aachen, Augsburg, Cologne, Dresden, Lübeck, München, Nürtingen, Würzburg
2023-08-31
Recruiting
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT03463954Malignant Neoplasm of Breast
Novian Health Inc.
Not applicable
122
Cologne
2023-08-09
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Leipzig, Aachen, Berlin, Cologne, Hanover, Mainz, Stuttgart, Villingen-Schwenningen
2023-08-08
Recruiting
Continuous Delivery Room Skin-to-skin-study for Moderate and Late Preterm Infants
NCT05975203Preterm Birth, Mother-Infant Interaction, Infant Development
University of Cologne
Not applicable
60
Cologne
2023-08-04
Recruiting
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
NCT05538806Pleural Mesothelioma
NovoCure Ltd.
Observational
198
Gauting, Regensburg, Harburg, Bremen, Göttingen, Dresden, Berlin, Cologne
2023-08-01
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
DrugUpadacitinib
AbbVie
Phase 3
1,014
Cologne, Mainz, Dresden, Buch, Frankfurt am Main
2023-07-25
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,089
Mannheim, Augsburg, München, Göttingen, Rostock, Cologne, Essen, Minden
2023-07-19
Recruiting
Regulation of Extracellular Sodium in End Stage Renal Disease Upon Volume and Electrolyte Challenges
NCT06408077Hyponatremia
University of Cologne
Not applicable
60
Cologne
2023-07-01
Recruiting
Mechanisms Of Disease Progression in Aortic Stenosis - the MODAS Study
NCT05851209Aortic Stenosis, Imaging, Pathogenesis, Disease Progression
Heinrich-Heine University, Duesseldorf
Observational
938
Bonn, Cologne, Düsseldorf
2023-07-01
Active, closed
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT05883644Advanced Hepatocellular Carcinoma
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
111
Berlin, Cologne, Frankfurt, Lübeck
2023-06-27
Recruiting
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
NCT05807932Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
DrugsMycophenolate Mofetil·Ara-C·Tacrolimus·Venetoclax
Heinrich-Heine University, Duesseldorf
Phase 1/2
38
Aachen, Düsseldorf, Cologne, Frankfurt, Jena, München
2023-06-26
Recruiting
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
NCT05701358Acute Myocardial Infarction, Coronary Artery Disease
Population Health Research Institute
Not applicable
5,100
Cologne, Dachau, Frankfurt, Hamburg, Heide
2023-06-22
Recruiting
Prospective Köln Bonn Registry for the Extraction of Pacmaker and ICD Leads
NCT06597578Infections, Pacemaker, Artificial, Defibrillators, Implantable
Evangelic Hospital Kalk Cologne
Observational
200
Cologne
2023-06-04
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Berlin, Cologne, Dresden, Essen, Gauting, Großhansdorf, Stuttgart, Würzburg
2023-05-31
Active, closed
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)
NCT05597761COVID-19, Adult, Immunocompromised Patients
Oliver Cornely, MD
Observational
49
Aachen, Cologne, Essen
2023-05-15
Active, closed
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
288
Freiburg im Breisgau, Cologne, Leipzig, Herne, Mainz
2023-04-21
Active, closed
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317Heart Failure
Edwards Lifesciences
Not applicable
100
Bad Oeynhausen, Cologne, Dresden, Heidelberg, Mainz
2023-04-01
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 3
1,135
Cologne, Duisburg, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Markkleeberg, Mettmann
2023-03-23
Recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,650
Bochum, Bonn, Cologne, Essen, Frankfurt, Jena, Leipzig, Regensburg
2023-03-21
Active, closed
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
NCT06039241Atopic Dermatitis
Sanofi
Observational
572
Aachen, Ahaus, Andernach, Berlin, Braunschweig, Buxtehude, Chemnitz, Cologne
2023-03-07
Recruiting
A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis
NCT06875336Extrapulmonary Tuberculosis
University of Cologne
Observational
150
Bonn, Borstel, Cologne, Frankfurt, Hamburg, Heidelberg
2023-03-06
Active, closed
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.
NCT05637112Systemic Lupus Erythematosus
AstraZeneca
Observational
551
Heidelberg, Erlangen, Bad Bramstedt, Schleswig-Holstein, Greifswald, Cologne, D Sseldorf, Herne
2023-02-27
Recruiting
Brain-Oscillation-Synchronized Stimulation to Enhance Motor Recovery in Early Subacute Stroke
NCT05600374Ischemic Stroke, Acute
University Hospital Tuebingen
Not applicable
144
Frankfurt a.M., Cologne, Münster, Tübingen
2023-02-06
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
DrugsEltrombopag·Ianalumab
Novartis Pharmaceuticals
Phase 3
152
Cologne, Dresden, Jena
2023-02-02
Recruiting
Dietary Interventions During Living Kidney Donations
NCT05709600Living-Kidney Donors
University of Cologne
Not applicable
80
Cologne
2023-02-01
Recruiting
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258Autosomal Recessive Polycystic Kidney (ARPKD)
DrugTolvaptan
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
20
Cologne
2023-01-23
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
DrugDordaviprone
Jazz Pharmaceuticals
Phase 3
510
Heidelberg, Augsburg, Regensburg, Frankfurt am Main, Bonn, Cologne, Essen, Berlin
2023-01-23
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Tübingen, Munich, Dresden, Lübeck, Chemnitz, Cologne, Erlangen, Planegg
2023-01-12
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Carfilzomib·Dexamethasone
Bristol-Myers Squibb
Phase 3
606
Ulm, Munich, Hanover, Dortmund, Kiel, Jena, Berlin, Cologne
2023-01-10
Recruiting
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
NCT06019130Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms, Nasopharynx Cancer
DrugsAvonex·Opdivo·Adrucil·Nivolumab
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 2
57
Aachen, Berlin, Bielefeld, Bonn, Cologne, Cottbus, Dortmund, Dresden
2023-01-10
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Augsburg, Cologne, Essen, Frankfurt, Leipzig, Munich, Münster
2023-01-05
Recruiting
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
NCT05306041HER2-positive Breast Cancer
DrugsPhesgo·Inavolisib
GBG Forschungs GmbH
Phase 2
170
Essen, Augsburg, Berlin, Bielefeld, Chemnitz, Cologne, Dessau, Dresden
2023-01-02
Recruiting
Laparoscopic Implantation of a Gastric Pacemaker in the Treatment of Gastroparesis
NCT06661668Gastroparesis, Gastroparesis Postoperative, Gastroparesis Nondiabetic, Gastroparesis With Diabetes Mellitus
Evangelic Hospital Kalk Cologne
Observational
50
Cologne
2023-01-01
Recruiting
DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device
NCT05543447Intracranial Aneurysm, Flow Diverter
Acandis GmbH
Observational
158
Augsburg, Berlin, Bremerhaven, Cologne, Dresden, Düsseldorf, Essen, Frankfurt am Main
2022-12-15
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
7,297
Aachen, Bad Krozingen, Bad Oeynhausen, Berlin, Bremen, Cologne, Dresden, Essen
2022-12-14
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
DrugTozorakimab
AstraZeneca
Phase 3
3,527
Augsburg, Berlin, Cologne, Hamburg, Hanover, Kiel, Leverkusen, Marburg
2022-12-13
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
DrugsCapmatinib·Amivantamab
Janssen Research & Development, LLC
Phase 1/2
57
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2022-12-13
Active, closed
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351Severe Hypertriglyceridemia
DrugOlezarsen
Ionis Pharmaceuticals, Inc.
Phase 3
885
Berlin, Cologne, Dresden, Witten
2022-12-13
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654Triple Negative Breast Cancer
DrugsSacituzumab Govitecan·Capecitabine·Pembrolizumab
Gilead Sciences
Phase 3
1,514
Augsburg, Berlin, Bielefeld, Bottrop, Braunschweig, Bremen, Cologne, Dortmund
2022-12-12
Active, closed
TARGET Study: Safety and Performance of the Cardiovalve TR Replacement System
NCT05486832Tricuspid Regurgitation
Cardiovalve Ltd.
Not applicable
157
Bad Oeynhausen, Berlin, Bonn, Cologne, Hamburg, Lübeck, Regensburg
2022-12-09
Recruiting
Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer
NCT05652348Gastric Cancer, Colon Cancer, Peritoneal Carcinomatosis
Technische Universität Dresden
Observational
48
Berlin, Cologne, Dresden, Ulm, Würzburg
2022-12-08
Recruiting
GMMG Multiple Myeloma Registry
NCT07111884Multiple Myeloma
Prof. Dr. Hartmut Goldschmidt
Observational
999
Berlin, Bielefeld, Bochum, Bonn, Chemnitz, Cologne, Darmstadt, Düsseldorf
2022-12-08
By invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
DrugEplontersen
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Cologne, Heidelberg, Homburg, Münster, Würzburg
2022-11-30
Active, closed
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183Cystic Fibrosis
DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
Phase 3
297
Berlin, Cologne, Essen, Frankfurt, Giessen, Halle, Hanover, Jena
2022-11-23
Active, closed
RESPONDER-HF Trial
NCT05425459Heart Failure, Heart Failure, Diastolic
Corvia Medical
Not applicable
750
Bad Krozingen, Bad Nauheim, Berlin, Cologne, Dresden, Düsseldorf, Freiburg im Breisgau, Göttingen
2022-11-17
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
DrugsDirect Anticoagulant·DOAC·Low molecular weight heparin·Lazertinib
Janssen Research & Development, LLC
Phase 2
520
Berlin, Cologne, Grosshandorf, Immenhausen, Würzburg
2022-11-11
Active, closed
Xeltis Hemodialysis Access Graft: aXess Pivotal Study
NCT05473299End-stage Renal Disease
Xeltis
Not applicable
120
Cologne
2022-11-04
Active, closed
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
NCT05535244Multiple Myeloma
DrugsCevostamab·Tocilizumab
Hoffmann-La Roche
Phase 1/2
90
Cologne, Hamburg, Würzburg
2022-10-17
Recruiting
Evaluation of Volume and Electrolyte Balance in Hyponatremia Treatment - a Prospective Observational Trial
NCT05692726Non-hypervolemic Hyponatremia
University of Cologne
Observational
50
Cologne
2022-10-15
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
864
Berlin, Cologne, Hamburg, Heidelberg, Leipzig, Mainz, Würzburg
2022-10-13
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
Cologne, Essen, Großhansdorf, Halle, Hamburg, Hemer, Karlsruhe, Lübeck
2022-10-12
Recruiting
VRAP-Heart - Virtual Reality Assisted Patient Empowerment for Interventions in Structural Heart Disease
NCT05552352Severe Aortic Valve Stenosis
Heinrich-Heine University, Duesseldorf
Not applicable
300
Düsseldorf, Cologne
2022-10-05
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Augsburg, Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dortmund, Düsseldorf
2022-10-04
Recruiting
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
NCT05443126NSCLC
DrugPemetrexed
Ellipses Pharma
Phase 1/2
265
Berlin, Cologne, München
2022-09-30
Active, closed
The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events
NCT05421286HIV-1-infection, Inflammation, AIDS
Rigshospitalet, Denmark
Observational
991
Bonn, Cologne, Eppendorf, Frankfurt am Main, Hamburg
2022-09-28
Recruiting
Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma
NCT05564091Primary Open Angle Glaucoma
Nova Eye, Inc.
Not applicable
78
Bonn, Cologne, Dortmund
2022-09-08
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Cologne, Düsseldorf
2022-09-05
By invitation
Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment
NCT05825898Tricuspid Regurgitation
Ottawa Heart Institute Research Corporation
Observational
3,500
Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg, Leipzig, Mainz
2022-09-01
Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
DrugsElacestrant·Abemaciclib
Stemline Therapeutics, Inc.
Phase 1/2
73
Bayreuth, Cologne, Dresden, Düsseldorf, Erlangen, Hanover, Leipzig, Worms
2022-08-31
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Munich, Ludwigshafen, Frankfurt am Main, Braunschweig, Cologne, Berlin, Mainz
2022-08-10
Active, closed
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
NCT05371080Herpes Zoster
GlaxoSmithKline
Phase 3
3,038
Wangen, Weinheim, Rednitzhembach, Wallerfing, Flörsheim, Cologne, Essen, Goch
2022-08-10
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
506
Cologne, Dresden, Berlin, Hanover, Herne
2022-08-04
Recruiting
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145KRAS P.G12C
DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Cologne, Hamburg
2022-08-03
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
DrugsAbraxane·Taxol·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 3
443
Berlin, Bonn, Bottrop, Cologne, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2022-07-25
Recruiting
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy
NCT05442710Sepsis, Severe
Artcline GmbH
Phase 2
142
Freiburg im Breisgau, Regensburg, Bonn, Cologne, Aue, Leipzig, Halle, Kiel
2022-07-24
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Berlin, Cologne, Dachau, Dresden, Duisburg, Erlangen, Essen, Frankfurt
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Ulm, Cologne
2022-07-21
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine
Gilead Sciences
Phase 3
623
Berlin, Bonn, Cologne, Essen, Hamburg, Heidelberg, Lübeck, Mannheim
2022-07-20
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
DrugDibotatug
Dren Bio
Phase 1/2
200
Berlin, Cologne, Leipzig
2022-07-13
Active, closed
Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)
NCT05062291Venous Stenosis, Venous Occlusion
Merit Medical Systems, Inc.
Observational
500
Berlin, Cologne
2022-06-23
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189Non-Small Cell Lung Cancer
DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib
BioNTech SE
Phase 1
320
Cologne, Frankfurt, Hamburg, Mainz
2022-06-17
Active, closed
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
NCT05382156Endogenous Cushing's Syndrome
DrugOsilodrostat
RECORDATI GROUP
Observational
206
Berlin, Cologne, Düsseldorf, Frankfurt, Hamburg, Munich, Oldenburg, Würzburg
2022-06-13
Recruiting
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor
DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam
Nuvalent Inc.
Phase 1/2
840
Cologne, Frankfurt, Großhansdorf, Heidelberg
2022-06-09
Active, closed
AMP SCZ® Observational Study: PREDICT-DPACC
NCT05905003Clinical High Risk, Psychosis, Remission, Conversion
Brigham and Women's Hospital
Observational
2,617
Cologne, Jena, Munich
2022-06-02
Active, closed
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974Non-small Cell Lung Cancer
DrugsParaplatin·Sacituzumab Govitecan·Keytruda·Cisplatin
Gilead Sciences
Phase 2
193
Berlin, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Halle
2022-05-30
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Aachen, Cologne, Dresden, Hamburg, Hanover, Lübeck, Mainz, Villingen-Schwenningen
2022-05-30
Active, closed
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257Limited-Stage Small Cell Lung Cancer
DrugsCarboplatin/cisplatin-etoposide·Serplulimab
Shanghai Henlius Biotech
Phase 3
511
Cologne, Travemünde
2022-05-17
Recruiting
Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence
NCT04976153Fecal Incontinence
Innovacell GmbH
Phase 3
290
Cologne, Mannheim
2022-05-11
Recruiting
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
NCT05090891Fibrodysplasia Ossificans Progressiva (FOP)
DrugINCB000928
Incyte Corporation
Phase 2
98
Cologne
2022-05-05
Active, closed
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
NCT05174650Intrahepatic Cholangiocarcinoma
DrugsTecentriq·Atezolizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
27
Bad Saarow, Berlin, Bonn, Cologne, Esslingen am Neckar, Frankfurt, Hanover, Krefeld
2022-04-20
Recruiting
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
NCT05197192Chronic Lymphocytic Leukemia
DrugsVenclyxto·Venclexta·Acalabrutinib·Obinutuzumab
German CLL Study Group
Phase 3
202
Bad Saarow, Berlin, Bremen, Cologne, Dortmund, Düsseldorf, Eschweiler, Essen
2022-04-19
Active, closed
Olorofim Aspergillus Infection Study
NCT05101187Invasive Aspergillosis
DrugAmbisome
F2G Biotech GmbH
Phase 3
225
Leipzig, Berlin, Cologne, Hamburg-Eppendorf
2022-03-31
Active, closed
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
DrugTulisokibart
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
154
Freiburg im Breisgau, Bad Nauheim, Hohenfelde B Bad Doberan, Cologne
2022-03-29
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436Chronic Lymphocytic Leukemia (CLL)
DrugsVenclexta·Obinutuzumab·Venetoclax
AbbVie
Phase 2
75
Mutlangen, Ulm, Landshut, Munich, Rostock, Cologne, Homburg, Dresden
2022-03-28
Active, closed
TRICuspid Intervention in Heart Failure Trial
NCT04634266Heart Failure Attributable to Severe Tricuspid Regurgitation
LMU Klinikum
Not applicable
360
Bad Oeynhausen, Berlin, Bernau, Bonn, Bremen, Cologne, Dortmund, Düsseldorf
2022-03-25
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
DrugsMosunetuzumab·Venclyxto·Venclexta·Tocilizumab
Hoffmann-La Roche
Phase 1
332
Augsburg, Cologne, Ulm
2022-03-07
Active, closed
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
NCT05153226Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS
DrugCyclophosphamide
DKMS gemeinnützige GmbH
Phase 3
640
Aachen, Augsburg, Chemnitz, Cologne, Dortmund, Dresden, Düsseldorf, Essen
2022-03-02
Active, closed
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
NCT05051033Mitral Valve Regurgitation
Annetine Gelijns
Not applicable
450
Cologne, Bad Oeynhausen, Bad Nauheim, Bad Rothenfelde, Berlin, Frankfurt, Freiburg im Breisgau, Hamburg
2022-02-21
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
DrugSetrusumab
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Cologne, Magdeburg, Würzburg
2022-02-21
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
DrugsDomvanalimab·Durvalumab
AstraZeneca
Phase 3
791
Berlin, Berlin-Zehlendorf, Braunschweig, Chemnitz, Cologne, Erlangen, Essen, Giessen
2022-02-18
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
DrugAnifrolumab
AstraZeneca
Phase 3
363
Cologne, Dresden, Hanover, Heidelberg, Kirchheim, Mainz Am Rhein
2022-02-15
Rows per page Showing 301–400 of 612
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/cologne?page=4

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 612 of those studies with a site in Cologne.

How many clinical trials are recruiting in Cologne?

312 of the 612 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 27 have not yet opened recruitment, 261 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.